迟发性泌尿生殖毒性的分次剂量敏感性:CHHiP 试验中 α/β 比值的分析
CHHiP 试验将 3216 例局限性前列腺癌患者随机分配至常规分割放疗(74 Gy/37 次)、中等大分割放疗(60 Gy/20 次)和 57 Gy/19 次三组,对 2206 例有放疗计划和随访评估者分析迟发性泌尿生殖毒性终点。含等效剂量校正的模型仅对尿痛和血尿三个终点显著改善拟合,拟合的 α/β 比值为 0.6 至 2 Gy,低于通常假设的 3 至 5 Gy。
要点
- 在尿痛 G1+、血尿 G1+ 和血尿 G2+ 三个终点中,含等效剂量校正的模型拟合显著优于未校正模型。
- 拟合的 α/β 比值分别为尿痛 G1+ 2.0 Gy、血尿 G1+ 0.9 Gy、血尿 G2+ 0.6 Gy。
- 作者认为,大分割对临床医生报告的泌尿生殖毒性的治疗增益可能低于通常假设的迟发 α/β 比值 3 至 5 Gy 所预期的水平。
核心结论
- 含等效剂量校正的模型显著改善了对尿痛和血尿终点的拟合,拟合的 α/β 比值较低,为 0.6 至 2 Gy。
- 作者认为,通过大分割降低临床医生报告的泌尿生殖毒性的治疗增益可能低于通常迟发 α/β 比值 3 至 5 Gy 假设所预期的水平。
研究设计与样本
- CHHiP 试验将 3216 例局限性前列腺癌患者按 1:1:1 随机分配至常规分割调强放疗(74 Gy/37 次)和两种中等大分割方案(60 Gy/20 次和 57 Gy/19 次)。
- 2206 例患者有可用的放疗计划和合适的随访评估。
- 分析合并了三种前瞻性评估的临床医生报告毒性量表,针对常见泌尿生殖终点:尿痛、血尿、尿失禁、尿流减弱/狭窄和尿频。
主要发现
- 含等效剂量校正的模型对仅 3 个终点的拟合显著优于未校正模型:尿痛 G1+(α/β=2.0 Gy;95%CI 1.2-3.2 Gy)、血尿 G1+(α/β=0.9 Gy;95%CI 0.1-2.2 Gy)和血尿 G2+(α/β=0.6 Gy;95%CI 0.1-1.7 Gy)。
- 对这 3 个终点,进一步纳入 2 个剂量修正因子(急性泌尿生殖毒性和既往经尿道前列腺电切术,仅血尿 G1+)改善了含等效剂量校正的模型,但 α/β 比值估计保持稳定。
关键数值与推荐
- 尿痛 G1+ 的 α/β=2.0 Gy(95%CI 1.2-3.2 Gy)。
- 血尿 G1+ 的 α/β=0.9 Gy(95%CI 0.1-2.2 Gy)。
- 血尿 G2+ 的 α/β=0.6 Gy(95%CI 0.1-1.7 Gy)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Moderately hypofractionated external beam intensity modulated radiation therapy (RT) for prostate cancer is now standard-of-care. Normal tissue toxicity responses to fraction size alteration are nonlinear: the linear-quadratic model is a widely used framework accounting for this, through the α/β ratio. Few α/β ratio estimates exist for human late genitourinary endpoints; here we provide estimates derived from a hypofractionation trial. METHODS AND MATERIALS: The CHHiP trial randomized 3216 men with localized prostate cancer 1:1:1 between conventionally fractionated intensity modulated RT (74 Gy/37 fractions (Fr)) and 2 moderately hypofractionated regimens (60 Gy/20 Fr and 57 Gy/19 Fr). RT plan and suitable follow-up assessment was available for 2206 men. Three prospectively assessed clinician-reported toxicity scales were amalgamated for common genitourinary endpoints: dysuria, hematuria, incontinence, reduced flow/stricture, and urine frequency. Per endpoint, only patients with baseline zero toxicity were included. Three models for endpoint grade ≥1 (G1+) and G2+ toxicity were fitted: Lyman Kutcher-Burman (LKB) without equivalent dose in 2 Gy/Fr (EQD2) correction [LKB-NoEQD2]; LKB with EQD2-correction [LKB-EQD2]; LKB-EQD2 with dose-modifying-factor (DMF) inclusion [LKB-EQD2-DMF]. DMFs were age, diabetes, hypertension, pelvic surgery, prior transurethral resection of prostate (TURP), overall treatment time and acute genitourinary toxicity (G2+). Bootstrapping generated 95% confidence intervals and unbiased performance estimates. Models were compared by likelihood ratio test. RESULTS: The LKB-EQD2 model significantly improved performance over LKB-NoEQD2 for just 3 endpoints: dysuria G1+ (α/β = 2.0 Gy; 95% confidence interval [CI], 1.2-3.2 Gy), hematuria G1+ (α/β = 0.9 Gy; 95% CI, 0.1-2.2 Gy) and hematuria G2+ (α/β = 0.6 Gy; 95% CI, 0.1-1.7 Gy). For these 3 endpoints, further incorporation of 2 DMFs improved on LKB-EQD2: acute genitourinary toxicity and prior TURP (hematuria G1+ only), but α/β ratio estimates remained stable. CONCLUSIONS: Inclusion of EQD2-correction significantly improved model fitting for dysuria and hematuria endpoints, where fitted α/β ratio estimates were low: 0.6 to 2 Gy. This suggests therapeutic gain for clinician-reported GU toxicity, through hypofractionation, might be lower than expected by typical late α/β ratio assumptions of 3 to 5 Gy.
引用
- Brand DH, Brüningk SC, Wilkins A, et al. The Fraction Size Sensitivity of Late Genitourinary Toxicity: Analysis of Alpha/Beta (α/β) Ratios in the CHHiP Trial. Int J Radiat Oncol Biol Phys. 2022. PMID: 35985457. doi:10.1016/j.ijrobp.2022.08.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。